Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
DFTX
Definium Therapeutics, Inc.
Definium Therapeutics, Inc. (DFTX) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B); its weakest is Profitability (C-).
Quantitative Factor Evaluation • Updated
Overall Rating
2.6
/ 5.0
C+
Value
C+
Factor Score
2.5
/ 5.0
Growth
C+
Factor Score
2.5
/ 5.0
Profitability
C-
Factor Score
1.9
/ 5.0
Momentum
B
Factor Score
3.3
/ 5.0
Revisions
C+
Factor Score
2.6
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
-19.0
EV / EBITDA
N/A
Rev Growth YoY
N/A
Gross Margin
0.0%
Price Return 3M
-19.1%
Price Return 12M
196.1%
Catalyst Signal
0.00
Market Cap
$4.7B
TTM Revenue
N/A
Price / Sales
N/A
ROE
-61.4%
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | C+ (2.5) | C+ (2.5) | C- (1.9) | B (3.3) | C+ (2.6) | C+ (2.6) |
| 2026-11-04 | C+ (2.5) | C+ (2.5) | D (1.4) | B (3.3) | C+ (2.7) | C (2.5) |
| 2026-10-28 | C+ (2.5) | C (2.5) | D (1.4) | B (3.3) | C+ (2.7) | C (2.5) |
| 2026-10-21 | C+ (2.5) | C (2.5) | D (1.4) | B (3.2) | C+ (2.6) | C (2.5) |
| 2026-10-14 | C+ (2.5) | C (2.5) | D (1.4) | B (3.3) | C+ (2.6) | C (2.5) |
Page
1
of
4